中国P站

Tregs; Gut microbiome; IL-10; Retinoic acid; Mucosal immunity; Inflammatory bowel disease; Dendritic cells; Epithelial cells; GALT; Short-chain fatty acids

Introduction

Foxp3+ regulatory T cells (Tregs) are vital for maintaining immune balance in the intestinal mucosa [1].

Their dysfunction can lead to inflammatory bowel disease. Understanding how to keep Tregs stable and functioning in the gut is key to creating effective treatments. The gut microbiome also plays a big role in T-cell regulation [2].

Specific bacteria or microbial byproducts can boost Treg differentiation and function, which helps suppress inflammation. On the flip side, an imbalance in the gut microbiome can mess with T-cell balance and lead to chronic inflammation. IL-10 is a critical cytokine for T-cell regulation in the mucosa [3].

It reduces the production of pro-inflammatory cytokines and encourages Treg development. Problems with IL-10 signaling can cause severe intestinal inflammation, highlighting its importance in gut health. Retinoic acid, a metabolite of vitamin A, is essential for shaping mucosal T-cell responses [4].

It helps T cells find their way to the gut and makes them more responsive to regulatory signals. A lack of retinoic acid can weaken mucosal immunity and increase the risk of infection. The interaction between T cells and dendritic cells (DCs) is crucial for starting and controlling mucosal immune responses [5].

DCs in the gut present antigens to T cells and provide co-stimulatory signals that determine how they differentiate and function. Different DC subsets can trigger different T-cell responses, influencing the balance between immunity and tolerance. Epithelial cells in the gut actively regulate T cells by producing cytokines and chemokines that affect T-cell movement and function [6].

They also express co-stimulatory molecules that can change T-cell activation. If the epithelial barrier is disrupted, it can lead to increased T-cell activation and inflammation. The gut-associated lymphoid tissue (GALT) provides a unique environment for T-cell education and regulation [7].

The GALT includes Peyer's patches, isolated lymphoid follicles, and the lamina propria. These structures facilitate antigen sampling, T-cell activation, and the induction of tolerance. Dietary factors can significantly impact mucosal T-cell regulation [8].

Specific nutrients, such as short-chain fatty acids (SCFAs) produced by gut bacteria, can promote Treg development and function. Dietary interventions may offer a promising approach for modulating mucosal immunity in inflammatory bowel disease. Emerging therapies targeting mucosal T-cell regulation hold promise for treating inflammatory bowel disease [9].

These include strategies to enhance Treg function, block pro-inflammatory T-cell responses, and modulate the gut microbiome. Clinical trials are underway to evaluate the efficacy of these approaches. Type 1 regulatory T cells (Tr1 cells) represent another important population of regulatory T cells in the intestinal mucosa [10].

They suppress immune responses through the production of IL-10 and other regulatory factors. Understanding the factors that promote Tr1 cell differentiation and function is crucial for developing novel therapies for IBD.

Description

The role of Foxp3+ regulatory T cells (Tregs) in maintaining intestinal immune homeostasis is pivotal [1]. These cells are essential for preventing excessive immune responses in the gut mucosa. Dysfunction or deficiency in Tregs can disrupt this delicate balance, leading to inflammatory bowel disease (IBD). Consequently, understanding the mechanisms that govern Treg stability and function is crucial for developing targeted therapies aimed at restoring immune balance in the gut.

The gut microbiome's influence on mucosal T-cell regulation is significant [2]. Specific bacterial species or microbial metabolites can promote the differentiation and function of Tregs, thereby suppressing inflammatory responses. For example, certain Clostridia strains have been shown to induce Treg production. Conversely, dysbiosis, an imbalance in the gut microbial community, can disrupt T-cell homeostasis and contribute to chronic inflammation, exacerbating conditions like IBD.

Interleukin-10 (IL-10) stands out as a crucial cytokine in mucosal T-cell regulation [3]. It plays a dual role by suppressing pro-inflammatory cytokine production and promoting the development of Tregs. This regulatory function is essential for maintaining gut homeostasis. Defects in IL-10 signaling can lead to severe intestinal inflammation, underscoring its importance in preventing uncontrolled immune reactions within the gut.

Retinoic acid, a vitamin A metabolite, plays a key role in shaping mucosal T-cell responses [4]. It promotes the differentiation of gut-homing T cells, enhancing their responsiveness to regulatory signals. This process is essential for maintaining mucosal immunity. Retinoic acid deficiency can impair mucosal immunity and increase susceptibility to infection, highlighting the importance of adequate vitamin A levels for gut health.

The interaction between T cells and dendritic cells (DCs) is critical for initiating and regulating mucosal immune responses [5]. DCs in the gut can present antigens to T cells and provide co-stimulatory signals that determine their differentiation and function. Different DC subsets can elicit distinct T-cell responses, influencing the balance between immunity and tolerance. This intricate interplay is vital for maintaining gut homeostasis and preventing excessive inflammation.

Epithelial cells in the gut actively participate in T-cell regulation by producing cytokines and chemokines that influence T-cell trafficking and function [6]. These cells also express co-stimulatory molecules that can modulate T-cell activation. Disruption of epithelial barrier function can lead to increased T-cell activation and inflammation, contributing to the pathogenesis of IBD and other inflammatory conditions.

The gut-associated lymphoid tissue (GALT) provides a unique microenvironment for T-cell education and regulation [7]. The GALT includes Peyer's patches, isolated lymphoid follicles, and the lamina propria. These structures facilitate antigen sampling, T-cell activation, and the induction of tolerance, all essential for maintaining immune homeostasis in the gut.

Dietary factors can significantly impact mucosal T-cell regulation [8]. Specific nutrients, such as short-chain fatty acids (SCFAs) produced by gut bacteria, can promote Treg development and function. Dietary interventions may offer a promising approach for modulating mucosal immunity in inflammatory bowel disease, providing a potential avenue for therapeutic intervention.

Emerging therapies targeting mucosal T-cell regulation hold promise for treating inflammatory bowel disease [9]. These include strategies to enhance Treg function, block pro-inflammatory T-cell responses, and modulate the gut microbiome. Clinical trials are underway to evaluate the efficacy of these approaches, offering hope for improved treatments for IBD patients.

Type 1 regulatory T cells (Tr1 cells) represent another important population of regulatory T cells in the intestinal mucosa [10]. They suppress immune responses through the production of IL-10 and other regulatory factors. Understanding the factors that promote Tr1 cell differentiation and function is crucial for developing novel therapies for IBD, expanding the arsenal of treatments targeting immune dysregulation in the gut.

Conclusion

T regulatory cells (Tregs) play a critical role in maintaining immune homeostasis within the intestinal mucosa, and their dysfunction can lead to inflammatory bowel disease. Understanding the mechanisms governing Treg stability and function in the gut is crucial for developing targeted therapies. The gut microbiome significantly influences mucosal T-cell regulation, with specific bacterial species or microbial metabolites promoting Treg differentiation and function, suppressing inflammatory responses. Dysbiosis, however, can disrupt T-cell homeostasis and contribute to chronic inflammation. IL-10 is a crucial cytokine in mucosal T-cell regulation, suppressing pro-inflammatory cytokine production and promoting Treg development; defects in IL-10 signaling can lead to severe intestinal inflammation. Retinoic acid, a vitamin A metabolite, plays a key role in shaping mucosal T-cell responses, promoting the differentiation of gut-homing T cells and enhancing their responsiveness to regulatory signals, while retinoic acid deficiency can impair mucosal immunity. The interaction between T cells and dendritic cells (DCs) is critical for initiating and regulating mucosal immune responses, with different DC subsets eliciting distinct T-cell responses. Epithelial cells in the gut actively participate in T-cell regulation by producing cytokines and chemokines that influence T-cell trafficking and function; disruption of epithelial barrier function can lead to increased T-cell activation and inflammation. The gut-associated lymphoid tissue (GALT) provides a unique microenvironment for T-cell education and regulation. Dietary factors can significantly impact mucosal T-cell regulation, with short-chain fatty acids (SCFAs) promoting Treg development and function. Emerging therapies targeting mucosal T-cell regulation hold promise for treating inflammatory bowel disease, including strategies to enhance Treg function, block pro-inflammatory T-cell responses, and modulate the gut microbiome. Type 1 regulatory T cells (Tr1 cells) also suppress immune responses through IL-10, making their differentiation and function important for IBD therapies.

References

1. Szczepanik A, Krzywinska E, Dymerska B (2012) .Nature 482:395-399.

   , ,

2. Kentaro A, Taro T, Kenya O (2013) .Nature 500:232-236.

   , ,

3. Akiko I, Stephan S, Takashi I (2004) .Journal of Immunology 172:6882-6886.

   , ,

4. Daniela M, Youngchul P, Guebum K (2007) .Science 317:256-260.

   , ,

5. Jennifer L, Khushnood R, Carolina A (2007) .Journal of Experimental Medicine 204:1757-1764.

   , ,

6. Warren S, Irina F, Pamela M (2007) .Journal of Clinical Investigation 117:514-521.

   , ,

7. Ana P, Robert J, David J (2014) .Mucosal Immunology 7:1184-1196.

   , ,

8. Peter M, Mark R, Nikolai P (2013) .Science 341:569-573.

   , ,

9. Richard S, Fiona P (2014) .Gastroenterology 146:1589-1599.

   , ,

10. Pedro A, Anne M, Junji H (2019) .Frontiers in Immunology 10:2767.

    , ,